DEF: NAI Seeks Shareholder Approval for Equity Plan Extension

Natural Alternatives International, Inc. is seeking stockholder approval for key proposals at its upcoming virtual annual meeting, including extending its equity incentive plan and increasing authorized shares.

Summary

• The Annual Meeting of Stockholders will be held virtually on Friday, December 5, 2025, at 11:00 AM Pacific Time.
• Stockholders of record as of October 13, 2025, are entitled to vote.
• Proposals include the election of Alan G. Dunn as a Class II director.
• Stockholders will vote on an amendment to the 2020 Equity Incentive Plan to extend its term by five years to January 1, 2031, and increase the number of shares authorized for issuance by 550,000, bringing the total to 1,250,000 shares.
• The ratification of Haskell & White LLP as the independent registered public accounting firm for the fiscal year ending June 30, 2026, is also on the agenda.
• An advisory vote on the compensation of named executive officers is included.
• Stockholders will also provide an advisory vote on the frequency of future executive compensation votes, with the Board recommending every three years.
• As of October 13, 2025, 6,176,778 shares of common stock were issued and outstanding, net of 3,328,128 treasury shares.
• Executive officers and directors collectively held 1,282,782 shares, representing approximately 20.8% of the outstanding common stock.
• The company reported a net income of -$13,575,000 for fiscal year 2025, compared to -$7,217,000 for fiscal year 2024.
• Total Shareholder Return (TSR) based on an initial $100 investment was -$45.51 for 2025 and -$16.39 for 2024.

Sentiment

Score: 3

Explanation: The filing presents a mixed picture. While corporate governance appears sound with independent directors and a clawback policy, the significant negative net income and Total Shareholder Return for the past two fiscal years are major concerns. The need to extend the equity plan and increase shares for retention suggests ongoing challenges in motivating and retaining key personnel amidst poor financial performance. The lack of consideration for pay-versus-performance in compensation decisions is also a negative indicator.

Positives

• All Board members and committee members attended all meetings during the fiscal year ended June 30, 2025, indicating strong engagement and oversight.
• The Board of Directors maintains a majority of independent directors (3 out of 4), aligning with Nasdaq listing standards.
• The Audit Committee members meet SEC independence standards and include two designated financial experts (Mr. Dunn and Ms. Matherly).
• A clawback and forfeiture policy was adopted in September 2023, enhancing corporate governance and executive accountability.
• All required Section 16(a) reports for directors and executive officers were filed timely.
• No related party transactions are currently anticipated or proposed, suggesting sound internal controls and ethical practices.

Negatives

• The company reported a significant net loss of -$13,575,000 for fiscal year 2025, which is a worsening from the -$7,217,000 loss in fiscal year 2024.
• Total Shareholder Return (TSR) for a $100 investment was negative, at -$45.51 for 2025 and -$16.39 for 2024, reflecting poor stock performance and value destruction.
• The 2020 Equity Incentive Plan is projected to be exhausted of shares in 2026 and beyond without the proposed amendment, potentially hindering future equity grants for employee retention.
• The Human Resources Committee did not consider the pay versus performance disclosure when making compensation decisions for fiscal year 2025, which could indicate a lack of alignment with shareholder interests.

Risks

• The virtual format of the Annual Meeting may limit participation for some stockholders, despite advance registration options.
• Failure to approve the amendment to the 2020 Equity Incentive Plan could result in insufficient shares for future equity grants, potentially impacting the company's ability to retain and incentivize critical personnel.
• The dual role of the CEO as Chair of the Board and largest stockholder, despite a majority of independent directors, could present potential governance challenges or perceived conflicts of interest.
• Continued negative net income and Total Shareholder Return pose a significant risk to the company's financial health and investor confidence.

Future Outlook

The company anticipates continuing to use its 2020 Equity Incentive Plan for equity-based grants to retain critical personnel and align incentives with stockholders, provided the proposed amendment to extend its term and increase authorized shares is approved. Without this approval, the plan will expire at the end of 2025 and be exhausted of shares in 2026, potentially impacting future compensation flexibility.

Management Comments

• We believe a four-member board, three of whom are independent members, is acceptable, if not ideal for the size and operations of our Company.
• We believe continuing our 2020 Plan and the flexibility to make grants under an extended 2020 Plan or creating a new plan on substantially similar terms are essential to retaining critical personnel and aligning the incentives of our personnel with our stockholders.
• Our Human Resources Committee believes the PEO's base salary reflects the value of the executive position and attributes the PEO brings to the Company, including tenure, experience, skill level and performance.
• Bonus payments when made have not been tied to any financial performance measure and have been and are planned to continue to be discretionary based on the evaluation of each individual's performance, change in responsibilities, their potential to contribute to the success of the Company, and the performance of the Company.

Industry Context

NA

Corporate Governance

Stakeholder Impact

• Shareholders: Potential dilution from the increased share authorization for the equity incentive plan. The virtual annual meeting format may impact participation for some. Negative financial performance (net income, TSR) directly impacts shareholder value.
• Employees/Management: The extension and increase in shares for the 2020 Equity Incentive Plan are crucial for retaining and motivating key personnel through equity awards. Executive compensation is subject to an advisory vote.
• Auditors: Haskell & White LLP's selection for fiscal year 2026 is up for ratification, confirming their ongoing role.

Next Steps

• Stockholders are to vote on director election, equity plan amendment, auditor ratification, executive compensation, and frequency of executive compensation votes at the Annual Meeting on December 5, 2025.
• If approved, the 2020 Equity Incentive Plan will be extended to January 1, 2031, and the number of shares available for issuance will increase.
• The Board of Directors will reconsider the selection of Haskell & White LLP if stockholders fail to ratify their selection.
• The Board and Human Resources Committee will review the voting results on executive compensation frequency and take them into consideration for future decisions.
• Stockholders wishing to submit proposals for the next annual meeting must do so by August 10, 2026.

Key Dates

Recommendation

The company has reported significant and worsening net losses for two consecutive fiscal years, with a negative Total Shareholder Return indicating substantial value destruction. While corporate governance measures like the clawback policy and independent board majority are positive, the fundamental financial performance is deeply concerning. The need to increase authorized shares for an equity incentive plan, coupled with the Human Resources Committee not considering pay-versus-performance in compensation decisions, suggests a disconnect between executive incentives and shareholder value. Given the sustained poor financial results and negative shareholder returns, a seasoned investor would likely recommend selling the stock to mitigate further losses.

Keywords

Natural Alternatives International, NAI, SEC Filing, Proxy Statement, DEF 14A, Annual Meeting, Stockholder Vote, Equity Incentive Plan, Executive Compensation, Corporate Governance, Director Election, Audit Firm Ratification, Financial Performance, Shareholder Return, Risk Management, Nutritional Supplements, Health and Wellness Industry